Inhibition of tumor growth and metastasis by non-small cell lung cancer cells transfected with cyclin D1-targeted siRNA

Oligonucleotides

Volumn 19, Issue 2, 2009, Pages 151-161

  Huang, Hu ^a,b   Hu, Yi De ^a,c   Li, Na ^b   Zhu, Yong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Pathology   (China)

^c Xinqiao Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; ANTINEOPLASTIC AGENT; CYCLIN D1; GELATINASE A; MESSENGER RNA; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CELL CYCLE ARREST; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; GENE THERAPY; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; RAC1 GTP-BINDING PROTEIN; RHOA GTP-BINDING PROTEIN; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66249119717     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2008.0174     Document Type: Article

References (55)

1. AFAR, D.E., MCLAUGHLIN, J., SHERR, C.J., WITTE, O.N., and ROUSSEL, M.F. (1995). Signaling by ABL oncogenes through cyclin D1. Proc. Natl. Acad. Sci. USA. 92, 9540-9544.
2. AMANATULLAH, D.F., ZAFONTE, B.T., ALBANESE, C., FU, M., MESSIERS, C., HASSELL, J., and PESTELL, R.G. (2001). Ras regulation of cyclin D1 promoter. Methods Enzymol. 333, 116-127.
3. BARNES, D.M., and GILLETT, C.E. (1998). Cyclin D1 in breast cancer. Breast Cancer Res. Treat. 52, 1-15.
4. BARTKOVA, J., LUKAS, J., MULLER, H., LUTZHOFT, D., STRAUSS, M., and BARTEK, J. (1994). Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer. 57, 353-361.
5. BIRKEDAL-HANSEN, H., MOORE, W.G., BODDEN, M.K., WINDSOR, L.J., BIRKEDAL-HANSEN, B., DECARLO, A., and ENGLER, J.A. (1993). Matrix metalloproteinases: a review. Crit. Rev. Oral. Biol. Med. 4, 197-250.
6. BODRUG, S.E., WARNER, B.J., BATH, M.L., LINDEMAN, G.J., HARRIS, A.W., and ADAMS, J.M. (1994). Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J. 13, 2124-2130.
7. BORTNER, D.M., and ROSENBERG, M.P. (1997). Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell. Biol. 17, 453-459.
8. CALLANAN, M., LEROUX, D., MAGAUD, J.P., and RIMOKH, R. (1996). Implication of cyclin D1 in malignant lymphoma. Crit. Rev. Oncog. 7, 191-203.
9. CAPACCIO, P., PRUNERI, G., CARBONI, N., PAGLIARI, A.V., QUATELA, M., CESANA, B.M., and PIGNATARO, L. (2000). Cyclin D1 expression is predictive of occult metastases in head and neck cancer patients with clinically negative cervical lymph nodes. Head Neck. 22, 234-240.
10. CHAN,H.M.,KRSTIC-DEMONACOS,M.,SMITH,L.,DEMONACOS, C., and LA THANGUE, N.B. (2001). Acetylation control of the retinoblastoma tumour-suppressor. Mol. Biol. Cell. 14, 2005-2015.
11. CHEN, H.Y., SHEN, C.H., TSAI, Y.T., LIN, F.C., HUANG, Y.P., and CHEN, R.H. (2004). Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol. Cell. Biol. 24, 10558-10572.
12. CHUNG, D.C. (2004). Cyclin D1 in human neuroendocrine: tumori-genesis. Ann. NY Acad. Sci. 1014, 209-217.
13. COUSSENS, L.M., and WERB, Z. (1996). Matrix metalloproteinases and the development of cancer. Chem. Biol. 3, 895-904.
14. DIEHL, J.A. (2002). Cycling to cancer with cyclin D1. Cancer Biol. Ther. 1, 226-231.
15. DOBASHI, Y., GOTO, A., FUKAYAMA, M., ABE, A., and OOI, A. (2004). Overexpression of cdk4/cyclin D1, a possible mediator of apoptosis and an indicator of prognosis in human primary lung carcinoma. Int. J. Cancer. 110, 532-541.
16. DRISCOLL, B., WU, L., BUCKLEY, S., HALL, F.L., ANDERSON, K.D., and WARBURTON, D. (1997). Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth. Am. J. Physiol. 273, L941-L949.
17. DWORAKOWSKA, D. (2005). Clinical significance of cyclin D1 expression in non-small cell lung cancer. Pneumonol. Alergol. Pol. 73, 297-330.
18. DWORAKOWSKA,D.,JASSEM,E.,JASSEM,J.,BOLTZE,C.,WIEDORN, K.H., DWORAKOWSKI, R., SKOKOWSKI, J., JASKIEWICZ, K., and CZESTOCHOWSKA, E. (2005). Prognostic value of cyclin D1 over-expression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC). J. Cancer Res. Clin. Oncol. 131, 479-485.
19. EDWARD, R.S., MEENHARD, H., and LIU, S.C. (2000). Prolonged response to antisense Cyclin D1 in a human squamous cancer xenograft model. Clin. Cancer Res. 6, 654-660.
20. GANSAUGE, S., GANSAUGE, F., RAMADANI, M., STOBBE, H., RAU, B., HARADA, N., and BEGER, H.G. (1997). Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 57, 1634-1637.
21. GUO, S.S., WU, X., SHIMOIDE, A.T., WONG, J., MOATAMED, F., and SAWICKI, M.P. (2003). Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. J. Endocrinol. 179, 73-79.
22. HALL, A. (1998). Rho GTPases and the actin cytoskeleton. Science. 279, 509-514.
23. HATSELL, S., ROWLANDS, T., HIREMATH, M., and COWIN, P. (2003). β-Catenin and Tcfs in mammary development and cancer. J. Mammary Gland Biol. Neoplasia. 8, 145-158.
24. HINDS, P.W., DOWDY, S.F., EATON, E.N., ARNOLD, A., and WEINBERG, R.A. (1994). Function of a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. USA. 91, 709-713.
25. HOTCHIN, N.A., and HALL, A. (1995). The assembly of integrin adhesion complexes requires both extracellular matrix and in-tracellular rho/rac GTPases. J. Cell. Biol. 131, 1857-1865.
26. HULIT, J., WANG, C., ALABANESE, C., DI VIZIO, D., MAHMOOD, R., AUGENLICHT, L.H., RUSSELL, R., and PESTELL, R.G. (2004). Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol. Cell. Biol. 24, 7598-7611.
27. ISHII, Y., PIRKMAIER, A., ALVAREZ, J.V., FRANK, D.A., KESELMAN, I., LOGOTHETIS, D., MANDELI, J., O'CONNELL, M.J., WAXMAN, S., and GERMAIN, D. (2006). Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. J. Natl. Cancer Inst. 98, 1238-1247.
28. KHAN, N., HADI, N., AFAQ, F., SYED, D.N., KWEON, M., and MUKHTAR, H. (2007). Pomegranate fruit extract inhibits prosurvival pathways in human A549 lung carcinoma cells and tumor growth in athymic nude mice. Carcinogenesis 28, 163-173.
29. LANGSENLEHNER, U., HOFMANN, G., SAMONIGG, H., KRIPPL, P., RENNER, W., and CLAR, H. (2005). Cyclin D1 genotype and breast cancer metastasis. Cancer Epidemiol. Biomarkers Prev. 14, 1844-1845.
30. LEE, R.J., ALBANESE, C., FU, M., D'AMICO, M., LIN, B., WATANABE, G., HAINES III, G.K., SIEGEL, P.M., HUNG, M.C., YARDEN, Y., HOROWITZ, J.M., MULLER, W.J., and PESTELL, R.G. (2000). Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol. Cell. Biol. 20, 672-683.
31. LIN, H.M., ZHAO, L., and CHENG, SY. (2002). Cyclin D1 is a ligandindependent co-repressor for thyroid hormone receptors. J. Biol. Chem. 277, 28733-28741.
32. LOVEC, H., SEWING, A., LUCIBELLO, F.C., MULLER, R., and MOROY, T. (1994). Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene. 9, 323-326.
33. MCMAHON, C., SUTHIPHONGCH AI, T., DIRENZO, J., and EWEN, M.E. (1999). P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc. Natl. Acad. Sci. USA. 96, 5382-5387.
34. MOTOKURA, T., and ARNOLD, A. (1993). PRAD1/cyclin D1 protooncogene: genomic organization, 5′ DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer. 7, 89-95.
35. MOTOKURA, T., BLOOM, T., KIM, H.G., JUPPNER, H., RUDERMAN, J.V., KRONEBERG, H.M., and ARNOLD, A. (1991). A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350, 512-515.
36. NEUMEISTER, P., PIXLEY, F.J., XIONG, Y., XIE, H., WU, K., ASHTON, A., CAMMER, M., CHAN, A., SYMONS, M., STANLEY, E.R., and PESTELL, R.G. (2003). Cyclin d1 governs adhesion and motility of macrophages. Mol. Biol. Cell. 14, 2005-2015.
37. NOBES, C.D., and HALL, A. (1995). Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 81, 53-62.
38. RATSCHILLER, D., HEIGHWAY, J., GUGGER, M., KAPPELER, A., PIRNIA, F., SCHMID, R.A., BORNER, M.M., and BETTICHER, D.C. (2003). Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J. Clin. Oncol. 21, 2085-2093.
39. RIDLEY, A.J., and HALL, A. (1992). The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stressbers in response to growth factors. Cell 7, 389-399.
40. RIDLEY, A.J., PATERSON, H.F., JOHNSTON, C.L., DIEKMANN, D., and HALL, A. (1992). The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70, 401-410.
41. ROBLES, A.I., RODRIGUEZ-PUEBLA, M.L., GLICK, A.B., TREMPUS, C., HANSEN, L., SICINSKI, P., TENNANT, R.W., WEINBERG, R.A., YUSPA, S.H., and CONTI, C.J. (1998). Reduced skin tumor development in cyclin Dl-deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev. 12, 2469-2474.
42. SHERR, C.J. (2000). The Pezcoller Lecture: cancer cell cycles revisited. Cancer Res. 60, 3689-3695.
43. STACEY, D.W. (2003). Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr. Opin. Cell. Biol. 15, 158-163.
44. STAMENKOVIC, I. (2003). Extracellular matrix remodelling: the role of matrix metalloproteinases. J. Pathol. 200, 448-464.
45. SU, J.L., SHIH, J.Y., YEN, M.L., JENG, Y.M., CHANG, C.C., HSIEH, C.Y., WEI, L.H., YANG, P.C., and KUO, M.L. (2004). Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Res. 64, 554-564.
46. SUN, S., ZIMMET, J.M., TOSELLI, P., THOMPSON, A., JACKSON, C.W., and RAVID, K. (2001). Overexpression of cyclin D1 moderately increases ploidy in megakaryocytes. Haematologica 86, 17-23.
47. URA, H., BONFIL, R.D., REICH, R., REDDEL, R., PFEIFER, A. HARRIS, C.C., and KLEIN-SZANTO, A.J. (1989). Expression of type IV collagenase and procollagen genes and its correlation with the tumorigenic, invasive, and metastatic abilities of oncogene-transformed human bronchial epithelial cells. Cancer Res. 49, 4615-4621.
48. WAAS, E.T., LOMME, R.M., DEGROOT, J., WOBBES, T., and HENDRIKS, T. (2002). Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br. J. Cancer. 86, 1876-1883.
49. WANG, T.C., CARDIFF, R.D., ZUKERBERG, L., LEES, E., ARNOLD, A., and SCHMIDT, E.V. (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369, 669-671.
50. WEINSTEIN, I.B. (1996). Relevance of cyclin D1 and other molecular markers to cancer chemoprevention. J. Cell. Biochem. Suppl. 25, 23-28.
51. YU,A.E.,HEWITT,R.E.,KLEINER,D.E.,andSTETLER-STEVENSON, W.G. (1996). Molecular regulation of cellular invasion - role of gelatinase A and TIMP-2. Biochem. Cell. Biol. 74, 823-831.
52. YU, Q., GENG, Y., and SICINSKI, P. (2001). Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-1021.
53. YU, Z., and WEINBERGER, P.M. (2005). Cyclin D1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin. Cancer Res. 11, 1160-1166.
54. ZHANG, Y.J., JIANG, W., CHEN, C.J., LEE, C.S., KAHN, S.M., SANTELLA, R.M., and WEINSTEIN, I.B. (1993). Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 196, 1010-1016.
55. ZWIJSEN, R.M., BUCKLE, R.S., HIJMANS, E.M., LOOMANS, C.J., and BERNARDS, R. (1998). Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev. 12, 3488-3498.